CORESTEM Inc Asset Resilience Ratio

Latest as of September 2025: 3.80%

CORESTEM Inc asset resilience ratio. CORESTEM Inc (166480) has an Asset Resilience Ratio of 3.80% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can CORESTEM Inc fund operations to measure how many days the company can operate on defensive assets alone.

Liquid Assets

₩4.30 Billion
≈ $2.92 Million USD Cash + Short-term Investments

Total Assets

₩113.27 Billion
≈ $76.76 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of CORESTEM Inc (2014–2024)

Asset resilience ratio of CORESTEM Inc from 2014 to 2024. This chart shows how CORESTEM Inc's Asset Resilience Ratio has changed over time. Read CORESTEM Inc debt and liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down CORESTEM Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see CORESTEM Inc (166480) total assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩4.30 Billion 3.8%
Total Liquid Assets ₩4.30 Billion 3.80%

Asset Resilience Insights

  • Limited Liquidity: CORESTEM Inc maintains only 3.80% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

CORESTEM Inc Industry Peers by Asset Resilience Ratio

Compare CORESTEM Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Verona Pharma plc
F:I9SA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Bavarian Nordic
CO:BAVA
Biotechnology 10.83%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 37.31%

CORESTEM Inc Asset Resilience Ratio by Year (2014–2024)

CORESTEM Inc asset resilience ratio by year from 2014 to 2024. The table below shows the annual Asset Resilience Ratio data for CORESTEM Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 1.89% ₩2.22 Billion
≈ $1.51 Million
₩117.46 Billion
≈ $79.60 Million
-1.55pp
2023-12-31 3.44% ₩2.70 Billion
≈ $1.83 Million
₩78.59 Billion
≈ $53.26 Million
+0.14pp
2022-12-31 3.30% ₩2.59 Billion
≈ $1.76 Million
₩78.61 Billion
≈ $53.28 Million
-47.10pp
2021-12-31 50.40% ₩68.75 Billion
≈ $46.59 Million
₩136.41 Billion
≈ $92.44 Million
-15.04pp
2020-12-31 65.43% ₩93.49 Billion
≈ $63.35 Million
₩142.87 Billion
≈ $96.82 Million
+29.59pp
2019-12-31 35.85% ₩30.70 Billion
≈ $20.81 Million
₩85.65 Billion
≈ $58.04 Million
+20.72pp
2018-12-31 15.12% ₩13.50 Billion
≈ $9.15 Million
₩89.26 Billion
≈ $60.49 Million
+7.95pp
2017-12-31 7.17% ₩6.50 Billion
≈ $4.40 Million
₩90.67 Billion
≈ $61.45 Million
+0.61pp
2016-12-31 6.56% ₩5.62 Billion
≈ $3.81 Million
₩85.69 Billion
≈ $58.07 Million
+4.56pp
2015-12-31 2.00% ₩1.50 Billion
≈ $1.02 Million
₩74.95 Billion
≈ $50.80 Million
-20.51pp
2014-12-31 22.51% ₩8.10 Billion
≈ $5.49 Million
₩35.99 Billion
≈ $24.39 Million
--
pp = percentage points

About CORESTEM Inc

KQ:166480 Korea Biotechnology
Market Cap
$30.92 Million
₩45.63 Billion KRW
Market Cap Rank
#23470 Global
#1613 in Korea
Share Price
₩1624.00
Change (1 day)
+1.69%
52-Week Range
₩1060.00 - ₩4800.00
All Time High
₩32150.00
About

CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatm… Read more